| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA716: Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency |
|
Medicine details |
|
| Medicine name | nivolumab / ipilimumab (Opdivo®) / (Yervoy®) |
| Formulation | 10 mg/ml concentrate for solution for infusion / 5 mg/ml concentrate for solution for infusion |
| Reference number | 4478 |
| Indication | Treatment of metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 30/04/2021 |
| NICE guidance | |